Literature DB >> 21104578

Comparison of HbA1c and OGTT criteria to diagnose diabetes among Chinese.

X L Dong1, Y Liu, Y Sun, C Sun, F M Fu, S L Wang, L Chen.   

Abstract

OBJECTIVE: To examine the sensitivity and specificity of HbA1c testing for the diagnosis of type 2 diabetes in high-risk adults in China and to compare the cardiaovascular risk factors between 2 groups of patients with glycemic status classified by the 2 different tests. RESEARCH DESIGN AND
METHOD: From a cross-sectional survey of prevalence of diabetes in China, we selected adults from the Jinan area of Shandong without known diabetes who underwent OGTT and HbA1c testing on the same day. Cardiovascular risk factors (blood pressure, body mass index, lipid levels) were compared among the subjects divided into 4 groups according to the 2 diabetes diagnostic criteria: true-diabetes, HbA1c-diagnosed diabetes, OGTT-diagnosed diabetes, and nondiabetes.
RESULTS: Among 701 subjects, 65 cases of diabetes were diagnosed by HbA1c ≥6.5% and 94 cases by OGTT. Comparing with OGTT,the sensitivity with level of HbA1c >6.5% was 48.2% and the specificity 97.8%. In total, 30.7% of subjects with HbA1c ≥6.5% were not classified as having diabetes by OGTT criteria, and 52% of subjects with diabetes according to OGTT criteria would be considered nondiabetic by HbA1c recommended criteria. The OGTT- and HbA1c-diabetes groups showed the same cardiovascular risk factors, the levels of which were higher than that for the nondiabetes group.
CONCLUSIONS: We found high specificity and low sensitivity with use of HbA1c level ≥6.5% to diagnose diabetes mellitus. The HbA1c test and OGTT did not reach full concordance. The 2 diagnostic criteria reflect similar levels of cardiovascular risk factors. © J. A. Barth Verlag in Georg Thieme Verlag KG Stuttgart · New York.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21104578     DOI: 10.1055/s-0030-1267183

Source DB:  PubMed          Journal:  Exp Clin Endocrinol Diabetes        ISSN: 0947-7349            Impact factor:   2.949


  6 in total

1.  Comprehensive identification of glycated peptides and their glycation motifs in plasma and erythrocytes of control and diabetic subjects.

Authors:  Qibin Zhang; Matthew E Monroe; Athena A Schepmoes; Therese R W Clauss; Marina A Gritsenko; Da Meng; Vladislav A Petyuk; Richard D Smith; Thomas O Metz
Journal:  J Proteome Res       Date:  2011-06-10       Impact factor: 4.466

2.  Can HbA1c replace OGTT for the diagnosis of diabetes mellitus among Chinese patients with impaired fasting glucose?

Authors:  Esther Y T Yu; Carlos K H Wong; S Y Ho; Samuel Y S Wong; Cindy L K Lam
Journal:  Fam Pract       Date:  2015-10-14       Impact factor: 2.267

3.  Community screening for pre-diabetes and diabetes using HbA1c levels in high-risk African Americans and Latinos.

Authors:  Mayer B Davidson; Petra Duran; Martin L Lee
Journal:  Ethn Dis       Date:  2014       Impact factor: 1.847

4.  Impact of the 2020 China Diabetes Society Guideline on the Prevalence of Diabetes Mellitus and Eligibility for Antidiabetic Treatment in China.

Authors:  Guoshuai Shi; Ni Zhu; Lin Qiu; Hong Yan; Lingxia Zeng; Duolao Wang; Shaonong Dang; Zhaoqing Li; Yijun Kang; Tao Chen; Chao Li
Journal:  Int J Gen Med       Date:  2021-10-12

5.  Change in visceral adiposity independently predicts a greater risk of developing type 2 diabetes over 10 years in Japanese Americans.

Authors:  Pandora L Wander; Edward J Boyko; Donna L Leonetti; Marguerite J McNeely; Steven E Kahn; Wilfred Y Fujimoto
Journal:  Diabetes Care       Date:  2012-09-10       Impact factor: 19.112

6.  Screening South Asians for type 2 diabetes and prediabetes: (1) comparing oral glucose tolerance and haemoglobin A1c test results and (2) comparing the two sets of metabolic profiles of individuals diagnosed with these two tests.

Authors:  Everlina Ma Vlaar; Wanda M Admiraal; Wim B Busschers; Frits Holleman; Vera Nierkens; Barend Jc Middelkoop; Karien Stronks; Irene Gm van Valkengoed
Journal:  BMC Endocr Disord       Date:  2013-02-25       Impact factor: 2.763

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.